329 related articles for article (PubMed ID: 38576614)
21. Talimogene Laherparepvec (T-VEC) and Other Oncolytic Viruses for the Treatment of Melanoma.
Bommareddy PK; Patel A; Hossain S; Kaufman HL
Am J Clin Dermatol; 2017 Feb; 18(1):1-15. PubMed ID: 27988837
[TBL] [Abstract][Full Text] [Related]
22. Therapy with oncolytic viruses: progress and challenges.
Shalhout SZ; Miller DM; Emerick KS; Kaufman HL
Nat Rev Clin Oncol; 2023 Mar; 20(3):160-177. PubMed ID: 36631681
[TBL] [Abstract][Full Text] [Related]
23. Oncolytic Viruses: Priming Time for Cancer Immunotherapy.
Russell L; Peng KW; Russell SJ; Diaz RM
BioDrugs; 2019 Oct; 33(5):485-501. PubMed ID: 31321623
[TBL] [Abstract][Full Text] [Related]
24. Efficacy and safety of oncolytic viruses in advanced or metastatic cancer: a network meta-analysis.
Xie R; Bi X; Shang B; Zhou A; Shi H; Shou J
Virol J; 2021 Jul; 18(1):158. PubMed ID: 34332591
[TBL] [Abstract][Full Text] [Related]
25. OV Modulators of the Paediatric Brain TIME: Current Status, Combination Strategies, Limitations and Future Directions.
Vazaios K; van Berkum RE; Calkoen FG; van der Lugt J; Hulleman E
Int J Mol Sci; 2024 May; 25(9):. PubMed ID: 38732225
[TBL] [Abstract][Full Text] [Related]
26. The safety of talimogene laherparepvec for the treatment of advanced melanoma.
Gangi A; Zager JS
Expert Opin Drug Saf; 2017 Feb; 16(2):265-269. PubMed ID: 27989216
[TBL] [Abstract][Full Text] [Related]
27. Engineered oncolytic viruses to treat melanoma: where are we now and what comes next?
Rothermel LD; Zager JS
Expert Opin Biol Ther; 2018 Dec; 18(12):1199-1207. PubMed ID: 30392405
[TBL] [Abstract][Full Text] [Related]
28. The viral approach to breast cancer immunotherapy.
Arab A; Behravan N; Razazn A; Barati N; Mosaffa F; Nicastro J; Slavcev R; Behravan J
J Cell Physiol; 2019 Feb; 234(2):1257-1267. PubMed ID: 30146692
[TBL] [Abstract][Full Text] [Related]
29. Application of oncolytic virus in tumor therapy.
Huang Z; Guo H; Lin L; Li S; Yang Y; Han Y; Huang W; Yang J
J Med Virol; 2023 Apr; 95(4):e28729. PubMed ID: 37185868
[TBL] [Abstract][Full Text] [Related]
30. Current status of clinical trials assessing oncolytic virus therapy for urological cancers.
Taguchi S; Fukuhara H; Homma Y; Todo T
Int J Urol; 2017 May; 24(5):342-351. PubMed ID: 28326624
[TBL] [Abstract][Full Text] [Related]
31. Oncolytic viruses encoding bispecific T cell engagers: a blueprint for emerging immunovirotherapies.
Heidbuechel JPW; Engeland CE
J Hematol Oncol; 2021 Apr; 14(1):63. PubMed ID: 33863363
[TBL] [Abstract][Full Text] [Related]
32. Tumor Tropism of DNA Viruses for Oncolytic Virotherapy.
Enow JA; Sheikh HI; Rahman MM
Viruses; 2023 Nov; 15(11):. PubMed ID: 38005938
[TBL] [Abstract][Full Text] [Related]
33. Oncolytic Viruses and Cancer Immunotherapy.
Malhotra J; Kim ES
Curr Oncol Rep; 2023 Jan; 25(1):19-28. PubMed ID: 36441447
[TBL] [Abstract][Full Text] [Related]
34. Immune System, Friend or Foe of Oncolytic Virotherapy?
Filley AC; Dey M
Front Oncol; 2017; 7():106. PubMed ID: 28589085
[TBL] [Abstract][Full Text] [Related]
35. The limiting factors of oncolytic virus immunotherapy and the approaches to overcome them.
Hu PY; Fan XM; Zhang YN; Wang SB; Wan WJ; Pan HY; Mou XZ
Appl Microbiol Biotechnol; 2020 Oct; 104(19):8231-8242. PubMed ID: 32816087
[TBL] [Abstract][Full Text] [Related]
36. The Current Status and Future Prospects of Oncolytic Viruses in Clinical Trials against Melanoma, Glioma, Pancreatic, and Breast Cancers.
Eissa IR; Bustos-Villalobos I; Ichinose T; Matsumura S; Naoe Y; Miyajima N; Morimoto D; Mukoyama N; Zhiwen W; Tanaka M; Hasegawa H; Sumigama S; Aleksic B; Kodera Y; Kasuya H
Cancers (Basel); 2018 Sep; 10(10):. PubMed ID: 30261620
[TBL] [Abstract][Full Text] [Related]
37. Virotherapy: From single agents to combinatorial treatments.
Malfitano AM; Di Somma S; Iannuzzi CA; Pentimalli F; Portella G
Biochem Pharmacol; 2020 Jul; 177():113986. PubMed ID: 32330494
[TBL] [Abstract][Full Text] [Related]
38. Oncolytic Viro-Immunotherapy: An Emerging Option in the Treatment of Gliomas.
Zeng J; Li X; Sander M; Zhang H; Yan G; Lin Y
Front Immunol; 2021; 12():721830. PubMed ID: 34675919
[TBL] [Abstract][Full Text] [Related]
39. Genetic modification of oncolytic viruses to enhance antitumor immunity.
Davola ME; Vito A; Wei J; El-Sayes N; Workenhe S; Mossman KL
Methods Enzymol; 2020; 635():231-250. PubMed ID: 32122548
[TBL] [Abstract][Full Text] [Related]
40. Review: Oncolytic virotherapy, updates and future directions.
Fountzilas C; Patel S; Mahalingam D
Oncotarget; 2017 Nov; 8(60):102617-102639. PubMed ID: 29254276
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
